dr. nahla farahat immunophenotyping of multiple myeloma
TRANSCRIPT
![Page 1: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/1.jpg)
PLASMA CELL MYELOMA IMMUNOPHENOTYPING
Nahla FarahatProfessor of clinical pathology
Alexandria University
![Page 2: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/2.jpg)
Plasma cell Neoplasms
Heterogeneous group of neoplasms characterized by expansion of clonal plasma cells in the bone marrow and usually associated with a detectable monoclonal protein in serum and/or urine.
![Page 3: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/3.jpg)
Origin of Plasma cells Plasma cells are terminally differentiated
activated B-cells, which have the ability to produce antibodies against a variety of antigens.
Once a clonal plasma cell population is established it has the potential to behave in a number of different ways.
This is translated into the clinically diverse plasma cell disorders which we encounter in everyday practice.
![Page 4: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/4.jpg)
Monoclonal gammopathy
The monoclonal gammopathies, in the presence of a clonal plasma cell proliferation can be subdivided into the following possible entities:
1. Monoclonal gammopathy of uncertain significance (MGUS)
2. Plasma cell myeloma (PCM) 3. Isolated plasmacytoma 4. Plasma cell leukaemia (PCL) 5. Primary amyloidosis 6. Immunoglobulin heavy chain and light chain
diseases
![Page 5: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/5.jpg)
Myeloma Pathogenesis
![Page 6: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/6.jpg)
The diagnosis of PCM is usually suspected when monoclonal gammopathy in the serum and/or Bence–Jones protein in the urine are found.
However, several types of plasma cell dyscrasia
show no or inconspicuous monoclonal protein.
In contrast, cases of amyloidosis may show monoclonal gammopathy, yet it is not necessarily neoplastic.
Therefore, the demonstration of myeloma cells is still the most important and definitive criterion for the diagnosis of PCM.
![Page 7: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/7.jpg)
Plasma cell Myeloma Bone marrow based multifocal Plasma cell
proliferative disorder associated with monoclonal protein in serum and/or urine and disseminated bone marrow involvement in most of cases.
In symptomatic phase, PCM is characterized by end organ affection in the form of:
Hypercalcemia Renal dysfunction Anemia Bone disease CRAB
![Page 8: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/8.jpg)
Plasma cells can be encountered in a number of neoplastic scenarios both in bone marrow and occasionally peripheral blood.
Also polyclonal, reactive plasma cells are also encountered in a number of different infective, inflammatory and neoplastic conditions.
![Page 9: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/9.jpg)
Reactive plasma cells
![Page 10: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/10.jpg)
In morphological terms, it can be difficult to differentiate reactive from clonal plasma cells unless plasma cells are present in gross excess, thereby making a clonal proliferation more likely.
Reactive plasma cells can show remarkable morphological diversity; the presence of multinucleate, pleomorphic and atypical plasma cells is well recognized in reactive scenarios and cannot be relied upon to indicate neoplasia
Flow cytometry studies are very capable at differentiating reactive from neoplastic plasma cell proliferations.
![Page 11: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/11.jpg)
![Page 12: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/12.jpg)
![Page 13: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/13.jpg)
\
![Page 14: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/14.jpg)
![Page 15: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/15.jpg)
![Page 16: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/16.jpg)
Flow cytometry and PCM In the past, MFC immunophenotyping of PC has
not been routinely applied in many laboratories for the diagnosis, classification and monitoring of patients with PC disorders.
FC is highly sensitive for the detection and characterization of plasma cells and has many advantages over morphological assessment.,
At present consensus exists about the great clinical utility of MFC in at least five different areas.
![Page 17: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/17.jpg)
Diagnosis by confirmation of the clonal nature of the plasma cells.
Differentiation of plasma cell dyscrasias from lymphoma.
Determining risk of progression Assessing disease prognosis Monitoring disease response to treatment
MRD.
Flow cytometry and PCM
![Page 18: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/18.jpg)
Markers of Plasma cells Normal plasma cells express CD45dim,
CD19, CD38 bright and CD138, together with restricted cytoplasmic light chain expression.
They do not express surface mmunoglobulin.
In the bone marrow, the brightest CD38+ cells are plasma cells.
CD138 is a specific marker for plasma cells
![Page 19: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/19.jpg)
Mateo et al J.Clin Oncol 2008
![Page 20: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/20.jpg)
Panel of MoAb (Triple combinations)FITC PE PercP
CD19 CD27 CD138
CD38 CD56 CD138
Cyt K Cytλ CD138
Gating on CD138 positive cells
![Page 21: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/21.jpg)
Panel of MoAb (Quadruple combinations)
FITC PE PE/CY5 APCCD38 CD56 CD19 CD45CD138 CD28 CD33 CD38CD20 CD117 CD138 CD38
Gating on bright CD38 positive cells
![Page 22: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/22.jpg)
FITC PE PerCP CY5.5
PC7 APC APCC750
1. CD27 CD56 CD19 CD38 CD138 CD452. CD81 CD117 CD19 CD38 CD138 CD45
Panel of MoAb (6 color combinations)
Leeds UK
![Page 23: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/23.jpg)
FITC PE PerCPCY5.5
PC7 APC APCC750
V450 BV510
CD38 CD56 CD45 CD19 CD117 CD81 CD138 CD27
Panel of MoAb (8 color combinations)
PETHEMA/Euroflow Group
![Page 24: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/24.jpg)
CD27
Expression of CD27 is uniformly seen in normal plasma cells as well as plasma cells in MGUS and its loss has been correlated with disease progression in patients with MGUS.
Progressive loss of CD27 has also been observed with disease progression in myeloma, and lack of CD27 expression at diagnosis was associated with shorter overall survival
![Page 25: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/25.jpg)
CD28 CD28 is aberrantly expressed on
neoplastic plasma cells in a fairly consistent manner.
Its expression level appears to increase with disease progression, with one study showing CD28 expression on plasma cells from 19% of MGUS and 41% of myeloma patients, and in 100% of human myeloma cell lines.
![Page 26: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/26.jpg)
CD117
CD117 (c-kit) is aberrantly expressed by a proportion of neoplastic plasma cells.
In one study, plasma cells from normal bone marrow samples did not show any reactivity for CD117, compared with 83 – 99% of CD117 positive plasma cells found in the marrows of one-third of myeloma patients.
Expression of CD117 has been associated with a good prognosis in myeloma
![Page 27: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/27.jpg)
CD33
CD33 is a myeloid antigen that can be aberrantly expressed by plasma cells.
In one study, CD33 positive patients had higher beta-2 microglobulin and lactate dehydrogenase levels and a higher incidence of anemia and thrombocytopenia than did CD33 negative patients.
The overall survival was significantly shorter in the CD33 positive group,
![Page 28: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/28.jpg)
CD20
CD20 is typically not expressed by normal plasma cells.
Several studies have suggested the presence of a small proportion of neoplastic plasma cells that express CD20 on their surface.
In one study in patients with multiple myeloma, CD20 expression was associated with small mature plasma cell morphology and with t(11;14)
![Page 29: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/29.jpg)
CD56
Expression of CD56 is commonly used to identify abnormal plasma cells, since normal plasma cells are typically CD56 negative.
Heterogeneity exists among clonal plasma cells with respect to CD56 expression.
CD56 negative patients had a higher incidence of extramedullary disease compared to CD56 positive patients.
Plasma cell leukemia are usually CD56 negative.
![Page 30: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/30.jpg)
CD81 is a tetraspanin widely expressed on B cells including mature PCs which is involved in the regulation of cell growth, motility, signaling and BM homing.
CD81 is strongly expressed on the surface of NPCs but MM cell lines are shown to underexpress it (negative or dim) .
CD81 positivity on myeloma cells is an independent prognostic factor for progression-free and overall survival and a marker for risk of progression in SMM
CD81
![Page 31: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/31.jpg)
Simultaneous assessment of the expression of CD38 and CD138 represents the best combination of markers for the specific identification of PC in hematological samples and its discrimination from other populations
of leukocytes and other hematopoietic cells. CD38 and CD138 are also expressed on
neoplastic plasma cells.
Gating strategy
![Page 32: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/32.jpg)
Positivity for these antigens is not discriminatory.
The intensity of expression does change. CD38 is dimmer and CD138 brighter in
malignant plasma cell populations compared to their normal counterpart.
They generates a well-defined gate for subsequent immunophenotypic analysis.
Gating strategy
![Page 33: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/33.jpg)
Gating strategy Measurement of 0.5 to 1 x 105 is typically
recommended for precise identification of PC and their accurate enumeration.
In PB and in BM samples with low (<1%) PC numbers, the usage of a second data acquisition step is required for higher sensitivity.
In this second step a broad ‘‘live-gate’’ drawn to select CD38 bright or CD138 positive events consisting of a minimum of 3,000 PC/tube should be obtained and stored
![Page 34: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/34.jpg)
In hypocellular and/or hemodiluted samples, analysis of a high number of PC is often difficult.
The European myeloma network recommends that at least 100 neoplastic plasma cell events be acquired for accurate enumeration. This will often require acquisition of a million or more total events
Gating strategy
![Page 35: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/35.jpg)
![Page 36: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/36.jpg)
How to differentiate between normal plasma cells and
myeloma cells The most important findings that
characterize malignant versus normal plasma cells are: absent or low expression of CD27, CD19 and/or CD45, and increased expression of CD28, CD33, CD117 and/or CD56.
Monoclonality for intracytoplasmic immunoglobulin light chains is the ultimate proof for the presence of an abnormal plasma cell population.
![Page 37: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/37.jpg)
![Page 38: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/38.jpg)
Classical phenotype of PCM
![Page 39: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/39.jpg)
Phenotypically aberrant PC typically show:
(1) underexpression of CD19, CD27, CD38, and CD45
(2) overexpression of CD28, CD33, CD81 and CD56
(3) asynchronous expression of CD20, CD117, and surface immunoglobulins (sIg)
Markers on Myeloma cells
![Page 40: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/40.jpg)
By using these markers with this gating strategy, even in cases where the expression of one of these markers is normally expressed (e.g. absence of CD56), simultaneous evaluation of antigenic aberrancies facilitates the discrimination between clonal and normal PC in virtually every PCM case.
![Page 41: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/41.jpg)
![Page 42: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/42.jpg)
Risk categories of PCM
![Page 43: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/43.jpg)
There is good correlation between flow and morphology in the assessment of bone marrow plasma cells, but it is important to note that morphological assessment of bone marrow plasma cell percentages is commonly higher than that determined by flow cytometry.
Assessment of Myeloma cells
![Page 44: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/44.jpg)
A 5- to 20-fold discrepancy in the proportion of plasma cells between the FCM sample and the aspirate smear is a common occurrence.
The finding of a plasma cell population at levels >1% as determined from the CD138/CD38 or CD45/CD38 dot plot would suggest some degree of plasmacytosis.
![Page 45: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/45.jpg)
Why are plasma cells less in flow ? There are a number of possible reasons for
this: 1. Malignant plasma cells are fragile and
surface membrane can be disrupted or lost during flow analysis.
2. Differences in plasma cell enrichment if serial rather than single pull marrow aspirations are taken (hemodilution).
3. Plasma cells often form clusters in bone marrow which are not freed up for single cell analysis in the cytometer. (focal distribution)
![Page 46: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/46.jpg)
Coexistence of normal and phenotypically aberrant PC is a constant finding in patients with MGUS, with most cases (>80%) displaying >5% normal PC within the overall BM PC compartment.
By contrast, only a small proportion (<15%) of all patients with symptomatic PCM display >5% N-PC/BMPC at diagnosis.
Therefore, the presence of >5% residual polyclonal PC at diagnosis has been found to be an accurate parameter for the discrimination between MGUS and PCM cases at diagnosis
How to differentiate between MGUS and PCM
![Page 47: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/47.jpg)
How to differentiate between MGUS and PCM
![Page 48: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/48.jpg)
![Page 49: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/49.jpg)
![Page 50: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/50.jpg)
How to differentiate between PCM and WM
Clonal myeloma cells Phenotype of B-NHL cells: CD19, CD20, CD45 and S
Immunoglobulins positive. CD 56 negative
![Page 51: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/51.jpg)
![Page 52: Dr. nahla farahat immunophenotyping of multiple myeloma](https://reader035.vdocument.in/reader035/viewer/2022081421/58e7d6ac1a28ab3a578b4fa7/html5/thumbnails/52.jpg)
Thank You